CSE: WBIO
Search

Latest News

News & Media

  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
December 5, 2024 PROPOSED SHARE CONSOLIDATION OF WPD’S COMMON SHARES
July 25, 2024 WPD ANNOUNCES SETTLEMENT OF DEBT FOR COMMON SHARES
June 7, 2024 WPD ANNOUNCES SETTLEMENT OF DEBT FOR COMMON SHARES
May 30, 2024 REINSTATEMENT OF TRADING OF WPD'S COMMON SHARES AND ANNUAL GENERAL MEETING
May 16, 2024 WPD Receives Full Revocation of Cease Trade Order
May 9, 2024 WPD Announces Filing of Annual Financial Statements and Provides Corporate Update
January 31, 2024 WPD Announces Filing of Annual Financial Statements and Provides Corporate Update
November 1, 2023 WPD Pharmaceuticals Sp. z o. o., received the second tranche of the funds
September 8, 2023 WPD Pharmaceuticals Sp. z o. o., received the first tranche of the funds
September 1, 2023 WPD's Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited
August 9, 2023 Signing of Letter of Intent with ACRX Investments Limited
June 15, 2023 WPD Pharmaceuticals Announces Closing of Convertible Debenture Private Placement
May 1, 2023 Convertible Debenture Offering, Update on Research Project Pipeline and Appointment of Additional Directors
January 18, 2023 WPD Pharmaceuticals Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in The Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
December 19, 2022 WPD Pharmaceuticals Announces First Two Sites Initiated In Poland In Clinical Trial of Berubicin In The Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)
December 1, 2022 WPD Pharmaceuticals announces share capital increase in Polish subsidiary
November 25, 2022 WPD Pharmaceuticals Announces First Patient Dosed in Phase 1B/2 Clinical Trial Of Annamycin In The Treatment Of Soft Tissue Sarcoma (STS) Lung Metastases and Provides Corporate Update
November 24, 2022 WPD Pharmaceuticals terminates grant agreement with the NCRD for the POIR.01.01.01-00-2382/20-00 project; resignation from the WPD’s Board of Directors
November 18, 2022 WPD Pharmaceuticals Provides a Corporate Update
May 16, 2022 WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences
March 7, 2022 WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project
February 9, 2022 WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary
February 3, 2022 WPD Pharmaceuticals Announces Appointment of New Director
February 1, 2022 WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity
January 25, 2022 WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech
July 2, 2021 Request for bids No 01/WPD108/2021
July 2, 2021 Zapytanie ofertowe nr 01/WPD108/2021

Convertible Debenture Offering, Update on Research Project Pipeline and Appointment of Additional Directors

WPD Pharmaceuticals Provides a Corporate Update

December 16, 2021 WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML
October 1, 2021 WPD Pharmaceuticals Announces AGSM Results
September 2, 2021 WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland
July 12, 2021 WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans
June 28, 2021 WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in 2H 2021
June 10, 2021 WPD Pharmaceuticals Invited to Join International Research Consortium
May 14, 2021 WPD Pharmaceuticals Provides Update on Audited Financial Statements
May 11, 2021 WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
May 5, 2021 WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
April 29, 2021 WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
April 27, 2021 WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas
April 13, 2021 WPD Pharmaceuticals and IAG to Host a Joint Webinar, “The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer”
April 6, 2021 WPD Pharmaceuticals Holds Pre-Submission Meeting with the European Medicines Agency and Receives Second Prepayment of C$954,248 From a Total C$7.4 Million Grant for Development of Berubicin
March 30, 2021 WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates
March 16, 2021 WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101
February 24, 2021 WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials
February 18, 2021 WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study
February 11, 2021 WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Further Support on Berubicin Trials
February 9, 2021 WPD Pharmaceuticals Announces US$1.5M Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin
February 5, 2021 WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug
January 28, 2021 WPD Pharmaceuticals to Participate in the 7th Annual LSX World Congress, a Leading Global Healthcare and Life Sciences Forum
January 14, 2021 WPD Pharmaceuticals Contracts Clinigen Clinical Supplies Management to Perform QP Certification of Berubicin for the Clinical Trials Authorization
January 6, 2021 WPD Pharmaceuticals to Collaborate With IAG to Deploy Artificial Intelligence and Quantitative Imaging to Assess the Effects of Berubicin
October 26, 2020 WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada
October 15, 2020 WPD Pharmaceuticals Appoints New Chief Medical Officer to Lead Phase I and II Clinic Trials
October 5, 2020 WPD Pharmaceuticals Receives the First Prepayment of $705,000 from Total $7.4 Million Grant for Development of Berubicin, and Receives $106,626 Government Covid-19 Cash Assistance
September 16, 2020 WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101
September 9, 2020 WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trials
September 1, 2020 WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate
August 17, 2020 WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO
July 28, 2020 WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors
July 23, 2020 WPD Pharmaceuticals Licensor Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
July 6, 2020 WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066
July 6, 2020 WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066
July 3, 2020 WPD Pharmaceuticals OTC Symbol Change to WPDPF
June 22, 2020 WPD Pharmaceuticals Licensor Announces Confirmatory in Vitro Analysis of WP1122
June 11, 2020 WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements
June 10, 2020 WPD Pharmaceuticals Clarifies Disclosure on Sublicensed Drug Candidate
May 28, 2020 WPD Pharmaceuticals Licensor Granted Another Key Patent for the Development of WPD101 Drug Candidate
May 15, 2020 WPD Pharmaceuticals To Resume Trading
May 5, 2020 WPD Pharmaceuticals Comments on SEC Order
April 30, 2020 WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial
April 29, 2020 WPD Pharmaceutical’s Annamycin Drug Approved for Accelerated European Clinical Trial
April 24, 2020 WPD Pharmaceuticals Announces FDA Application Under The Orphan Drug Act Was Submitted By License Partner for Brain Cancer Drug, Berubicin
April 23, 2020 WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Evidence of Cardiotoxicity
April 21, 2020 WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences
April 16, 2020 WPD Pharmaceuticals’ License Partner, Moleculin Biotech to Host Conference Call to Discuss COVID-19 Potential in WP1122 Drug Candidate
April 9, 2020 WPD Pharmaceuticals Clarifies News on Licensed Drug Candidate
April 9, 2020 WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%
April 8, 2020 WPD Pharmaceuticals Provides Corporate Update
April 1, 2020 WPD Pharmaceuticals Welcome Dr. Waldemar Debinski to its Scientific Advisory Board
March 24, 2020 WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
March 19, 2020 WPD Pharmaceuticals’ WP1122 Drug to Be Tested on a Range of Viruses Including Coronavirus
March 13, 2020 WPD Pharmaceuticals Announces Brain Cancer Patient From Berubicin Phase 1 Trial Remains Cancer Free
March 11, 2020 WPD Pharmaceuticals Received $800,000 Reimbursement From $7.4 Million Government Grant for Development of Glioblastoma Drug
March 4, 2020 WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance
February 27, 2020 WPD Pharmaceuticals’ Annamycin Received Positive Interim Results from Phase 1/2 Clinical Studies in Acute Myeloid Leukemia
February 24, 2020 WPD Pharmaceuticals Granted Key Patent Exclusively Licensed From Wake Forest University
February 20, 2020 WPD Pharmaceuticals' Stat3 Inhibitor Received FDA Approval of Ind Status in Pediatric Brain Cancer Trial
February 18, 2020 WPD Pharmaceuticals’ Wp1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials
February 12, 2020 WPD Pharmaceuticals to Conduct Clinical Trials in Pediatric Brain Tumors Through Collaboration with Cns Pharmaceuticals
February 10, 2020 WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery
February 5, 2020 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation
February 3, 2020 WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates Bringing Total Development Funding Spent on Drugs Under License to Over USD $100 Million
January 31, 2020 WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates
January 29, 2020 WPD Pharmaceuticals Receives European Patent for Cancer Targeting Drugs
January 14, 2020 Westcot Ventures Corp. Announces Name Change to “WPD Pharmaceuticals Inc.”
January 9, 2020 WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent
January 8, 2020 WPD Pharmaceuticals Provides 2019 Corporate Year End Review
December 27, 2019 Westcot Ventures Corp. Announces Listing on the Canadian Securities Exchange
December 23, 2019 Westcot Ventures Corp. Announces Closing of Transaction of WPD Pharmaceuticals Sp. Z.o.o.
December 16, 2019 Westcot Ventures Corp. Announces Amending Agreement with WPD Pharmaceuticals Sp. Z.o.o., Voluntary Delisting from the TSX Venture Exchange and Proposed Listing on Canadian Securities Exchange
November 1, 2019 Westcot Announces Results of the Annual General and Special Meeting of Shareholders
July 17, 2019 Westcot Ventures Corp. Announces Definitive Agreement with WPD Pharmaceuticals Inc
May 2, 2019 Westcot Ventures Corp. Announces Letter of Intent for Reverse Takeover with WPD Pharmaceuticals Inc. and Director Appointment
March 31, 2019 WESTCOT ANNOUNCES BOARD AND MANAGEMENT CHANGES; TERMINATION OF SHARE EXCHANGE AGREMENT
December 21, 2018 WESTCOT ANNOUNCES CHANGE OF AUDITOR
August 28, 2018 WESTCOT CLOSES PRIVATE PLACEMENTS TO RAISE UP TO $2,764,998.60 AND ENTERS INTO SHARE EXCHANGE AGREEMENT
July 27, 2018 WESTCOT ANNOUNCES PRIVATE PLACEMENTS TO RAISE UP TO $3,100,000 AND PROVIDES CORPORATE UPDATE
July 19, 2018 WESTCOT ANNOUNCES AGM RESULTS
July 10, 2018 WESTCOT PROPOSES 2:1 FORWARD SPLIT
June 7, 2018 WESTCOT VENTURES CORP. ANNOUNCES PROPOSED CHANGE OF BUSINESS
November 21, 2017 WESTCOT CLOSES PRIVATE PLACEMENT AND ANNOUNCES MANAGEMENT CHANGES
October 18, 2017 WESTCOT ANNOUNCES PRIVATE PLACEMENT
October 10, 2017 WESTCOT REPORTS DEBENTURES CONVERSION
September 18, 2017 WESTCOT ANNOUNCES CHANGE OF TRADING SYMBOL
September 14, 2017 SPARROW ANNOUNCES REINSTATEMENT TO TRADING, CONSOLIDATION, AND NAME CHANGE TO WESTCOT VENTURES CORP.
August 11, 2017 SPARROW ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER
June 23, 2017 SPARROW CLOSES FINAL TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING AND APPOINTS DIRECTOR
March 17, 2017 SPARROW CLOSES THIRD TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING
February 8, 2017 SPARROW ANNOUNCES REVOCATION OF CEASE TRADE ORDERS
January 17, 2017 SPARROW CLOSES SECOND TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING
October 31, 2016 SPARROW ANNOUNCES NEW DIRECTOR APPOINTMENT
October 3, 2016 SPARROW ANNOUNCES FIRST CLOSING OF SECURED CONVERTIBLE DEBENTURES OFFERING AND APPOINTS DIRECTOR
August 18, 2016 SPARROW ANNOUNCES PARTIAL REVOCATION OF CEASE TRADE ORDER
August 24, 2015 SPARROW ANNOUNCES RESIGNATION OF DIRECTOR
June 25, 2015 SPARROW ANNOUNCES RESIGNATION OF CFO
June 17, 2014 SPARROW ANNOUNCES GRANT OF OPTIONS
June 16, 2014 TRANSFER OF LISTING TO NEX
June 4, 2014 Sparrow Announces Unsecured Loan
May 1, 2013 Sparrow Adopts Advance Notice Policy for Future Shareholder Meetings
May 1, 2013 Sparrow Adopts Advance Notice Policy for Future Shareholder Meetings
May 1, 2013 Sparrow Adopts Advance Notice Policy for Future Shareholder Meetings
January 20, 2012 SPARRROW ANNOUNCES NEW APPOINTMENT TO ITS MANAGEMENT TEAM
January 20, 2012 SPARRROW ANNOUNCES NEW APPOINTMENT TO ITS MANAGEMENT TEAM
June 27, 2011 SPARROW ADDRESSES POSTAL STRIKE EFFECTS ON AGM
May 27, 2011 SPARROW ANNOUNCES GRANT OF OPTIONS
April 13, 2011 Sparrow Announces Director Resignation
October 7, 2010 SPARROW VENTURES ANNOUNCES GRANT OF OPTIONS
October 1, 2010 SPARROW APPOINTS RODNEY STEVENS AS SECRETARY
August 31, 2010 SPARROW VENTURES ANNOUNCES GRANT OF OPTIONS
August 26, 2010 SPARROW VENTURES CORP. COMPLETES QUALIFYING TRANSACTION
August 16, 2010 SPARROW VENTURES CORP. FILES FILING STATEMENT REGARDING QUALIFYING TRANSACTION WITH FULL METAL MINERALS LTD.
May 26, 2010 SPARROW VENTURES CORP. TERMINATES QUALIFYING TRANSACTION WITH NETWORK ENTERTAINMENT AND ANNOUNCES LETTER AGREEMENT WITH FULL METAL MINERALS FOR EXECUTION OF QUALIFYING TRANSACTION
May 3, 2010 SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT
April 16, 2010 SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT
February 22, 2010 SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT
February 17, 2010 SPARROW VENTURES CORP. ANNOUNCES PROPOSED QUALIFYING TRANSACTION
December 30, 2009 SPARROW CLOSES FINANCING
November 10, 2009 SPARROW ANNOUNCES FINANCING
October 8, 2009 SPARROW VENTURES CORP. TERMINATES LETTER OF INTENT AND QUALIFYING TRANSACTION WITH JSX ENERGY (THAILAND) LIMITED
March 19, 2009 SPARROW VENTURES CORP. ANNOUNCES PROPOSED QUALIFYING TRANSACTION
May 21, 2008 INITIAL PUBLIC OFFERING COMPLETED